期刊文献+

硼替佐米或联合三氧化二砷治疗HL-60白血病细胞移植瘤裸鼠的实验研究 被引量:2

Effect of bortezomib used alone or in combination with arsenic trioxide on HL-60 cell xenograft in nude mice
下载PDF
导出
摘要 目的探讨硼替佐米(Bor)单独和联合三氧化二砷(As2O3)对HL-60白血病细胞移植瘤裸鼠的抗瘤作用、作用机制及药物毒性。方法建立皮下移植瘤裸鼠模型,随机分为4组,即生理盐水(NS)组、Bor单药组、As2O3单药组、Bor联合As2O3组,比较各组的抑瘤作用和裸鼠一般状态的变化,并对移植瘤进行细胞凋亡和免疫组化检测。结果Bor单独或联合As2O3均能抑制移植瘤生长和延长裸鼠生存时间,并诱导肿瘤细胞凋亡和抑制其增殖,其中以联合用药组效果最好,且未引起重要脏器损害。结论Bor联合As2O3对HL-60白血病细胞移植瘤裸鼠具有显著的抗瘤作用,此作用可能与诱导肿瘤细胞凋亡和抑制其增殖有关,且无明显毒副作用。 Objective To assess the antitumor efficacy and adverse effects of bortezomib either used alone or in combination with arsenic trioxide for transplanted tumor in nude mice.Methods Nude mice bearing HL-60 cell xenografts were randomized into 4 groups to receive treatment with normal saline,bortezomib,arsenic trioxide,bortezomib plus arsenic trioxide.The tumor growth inhibition and general condition of the nude mice were observed,and in situ TUNEL assay and immunohistochemistry were performed on the transplanted tumors.Results Bortezomib alone and in combination with arsenic trioxide could both inhibit the growth of the transplanted tumors,prolong the survival of the nude mice,and induce cell apoptosis and growth inhibition of the HL-60 cells in vivo,and the combined administration exhibited even better effects.The administration was well tolerated with causing manifest vital organ damages in the mice.Conclusions Bortezomib in combination with arsenic trioxide has significant antitumor effect in nude mice bearing HL-60 cell xenografts possibly by inducing HL-60 cell apoptosis and growth inhibition without produceing no significant adverse effects.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2007年第10期1504-1506,共3页 Journal of Southern Medical University
基金 广东省社会发展科技计划攻关课题(B30202) 广东省科技计划项目(0711220700157)~~
关键词 硼替佐米 三氧化二砷 白血病 裸鼠 bortezomib arsenic trioxide leukemia nude mice
  • 相关文献

参考文献8

  • 1孙启鑫,孟凡义,扶云碧,李利,田帅.硼替佐米或联合三氧化二砷诱导HL-60细胞凋亡实验研究[J].南方医科大学学报,2007,27(7):1022-1025. 被引量:4
  • 2Tactic R, Rosen F, Abramson I, et al. Use of nude mouse xenogratts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenogratts [ J ]. Cancer Treat Rep, 1987, 71 (3): 297-304.
  • 3刘琳,赵伟,秦叔逵,李苏宜,邱少敏,王南瑶,陈惠英.三氧化二砷抗裸鼠人结肠癌移植瘤作用及其机制的研究[J].中国肿瘤临床,2005,32(18):1067-1070. 被引量:10
  • 4Tan C, Waldmarm TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia [J]. Cancer Res, 2002, 62(4): 1083-6.
  • 5Satou Y, Nosaka K, Koya Y, et al. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro [J]. Leukemia, 2004, 18(8): 1357-63.
  • 6Cortes J, Thomas D, Koller C, et al. Phase I study ofbortezomib in refi'actory or relapsed acute leukemias [J]. Clin Cancer Res, 2004, 10(10): 3371-6.
  • 7Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies [J]. Blood, 2005, 105(8): 3058-65.
  • 8Attar EC, De Angelo D J, Sirulnik A, et al. Addition of bortezomib (Velcade) to AML induction chemotherapy is well tolerated and results in a high complete remission rate [J]. Blood, 2005, 106(11): 780a.

二级参考文献20

  • 1刘琳,邱少敏,赵伟,夏海鸣,秦叔逵,陈惠英.三氧化二砷诱导人类大肠癌细胞凋亡的分子机制[J].世界华人消化杂志,2004,12(7):1550-1554. 被引量:19
  • 2斯佩克特 D L 戈德曼 R D 莱因万德 L A.细胞实验指南[M].北京:科学出版社,2001.685-687.
  • 3Mer J. Ancient remedy perform new tricks [J]. Science, 1996, 273(5275):578.
  • 4Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide(As2O3)in the treatment of acute Promyelocytic leukemia (APL): Ⅰ. As2O3exertsdose-dependent dual effects on APL cells [J]. Blood, 1997,89(9) :3345 ~3353.
  • 5Horton TM,Gannavarapu A,Blaney SM,et al.Bortezomib interactions with chemotherapy agents in acute leukemia in vitro[J].Cancer Chemother Pharmacol,2006,58(1):13-23.
  • 6Dai Y,Rahmani M,Pei XY,et al.Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and-independent mechanisms[J].Blood,2004,104(2):509-18.
  • 7Dai Y,Rahmani M,Grant S,et al.Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK-and NF-kappaB-dependent process[J].Oncogene,2003,22(46):7108-22.
  • 8Smolewski P,Duechler M,Linke A,et al.Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells[J].Leuk Res,2006,30(12):1521-9.
  • 9Voorhees PM,Dees EC,O'Neil B,et al.The proteasome as a target for cancer therapy[J].Clin Cancer Res,2003,9(17):6316-25.
  • 10Gatto S,Scappini B,Pham L,et al.The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate[J].Haematologica,2003,88(8):853-63.

共引文献12

同被引文献8

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部